179 related articles for article (PubMed ID: 6541340)
21. Primary cisplatin, methotrexate and vinblastine aiming at bladder preservation in invasive bladder cancer: multivariate analysis on prognostic factors.
Angulo JC; Sanchez-Chapado M; Lopez JI; Flores N
J Urol; 1996 Jun; 155(6):1897-902. PubMed ID: 8618282
[TBL] [Abstract][Full Text] [Related]
22. Antimetastatic activity of the new platinum analog [Pt(cis-dach) (DPPE).2NO3] in a metastatic model of human bladder cancer.
Chang SG; Kim JI; Jung JC; Rho YS; Lee KT; An Z; Wang X; Hoffman RM
Anticancer Res; 1997; 17(5A):3239-42. PubMed ID: 9413154
[TBL] [Abstract][Full Text] [Related]
23. [Epithelial bladder tumor induction in rats with N-(4-(5-nitro-2-furyl)-2-thiazolyl)formamide].
Vlasov NN; Pliss GB; Balin VV
Vopr Onkol; 1980; 26(3):63-7. PubMed ID: 7368659
[TBL] [Abstract][Full Text] [Related]
24. Effects of urine and continued exposure to carcinogen on progression of early neoplastic urinary bladder lesions.
Rowland RG; Henneberry MO; Oyasu R; Grayhack JT
Cancer Res; 1980 Dec; 40(12):4524-7. PubMed ID: 7438086
[TBL] [Abstract][Full Text] [Related]
25. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
[TBL] [Abstract][Full Text] [Related]
26. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
27. NTP Toxicology and Carcinogenesis Studies of 1-Amino-2,4-Dibromoanthraquinone (CAS No. 81-49-2) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1996 Aug; 383():1-370. PubMed ID: 12692653
[TBL] [Abstract][Full Text] [Related]
28. Systemic chemotherapy of murine bladder cancer.
Soloway MS; Niell HB; Matheny RB; Blatnik A
Urology; 1984 Apr; 23(4 Suppl):129-34. PubMed ID: 6538713
[No Abstract] [Full Text] [Related]
29. [Cyclooxygenase-2-expression in bladder cancer: tumor-biological and clinical implications].
Wülfing C; Eltze E; Von Struensee D; Wülfing P; Bode ME; Bettendorf O; Piechota H; Hertle L
Aktuelle Urol; 2004 Aug; 35(4):331-8. PubMed ID: 15459875
[TBL] [Abstract][Full Text] [Related]
30. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
[TBL] [Abstract][Full Text] [Related]
31. Establishment and characterization of a transplantable dibutylnitrosamine-induced mouse bladder tumor line FCB.
Flaks A; Flaks B
Cancer Res; 1973 Dec; 33(12):3285-92. PubMed ID: 4760540
[No Abstract] [Full Text] [Related]
32. [Characterization of a novel transplantable orthotopic nude mouse model with xenografted human bladder transitional cell tumor (BIU-87)].
Li C; Yan RP; Yuan GH; Feng YG; Wang JS; Gao X; Huang YS; Zhou JB; Xie SS
Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):733-6. PubMed ID: 17366782
[TBL] [Abstract][Full Text] [Related]
33. Tissue culture of urinary bladder tumor induced in a rat by N-butyl-N-(-4-hydroxybutyl)nitrosamine: establishment of cell line, Nara Bladder Tumor II.
Toyoshima K; Ito N; Hiasa Y; Kamamoto Y; Makiura S
J Natl Cancer Inst; 1971 Nov; 47(5):979-85. PubMed ID: 4941696
[No Abstract] [Full Text] [Related]
34. Applications of the xenograft as a model of invasive transitional cell carcinoma of the bladder.
Russell PJ; Raghavan D; Philips J; Gregory P
Prog Clin Biol Res; 1988; 260():167-81. PubMed ID: 3362878
[TBL] [Abstract][Full Text] [Related]
35. Single and combination chemotherapy for primary murine bladder cancer.
Soloway MS
Cancer; 1975 Aug; 36(2):333-40. PubMed ID: 1157004
[TBL] [Abstract][Full Text] [Related]
36. In vitro characterization of four N-[4-(5-nitro-2-furyl)-2-thiazolyl] formamide (FANFT) induced mouse bladder tumors.
Mickey DD; Mickey GH; Murphy WM; Niell HB; Soloway MS
J Urol; 1982 Jun; 127(6):1233-7. PubMed ID: 7087044
[TBL] [Abstract][Full Text] [Related]
37. Neovascularization in rats during urinary bladder carcinogenesis induced by N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide.
Cohen SM; Tatematsu M; Shinohara Y; Nakanishi K; Ito N
J Natl Cancer Inst; 1980 Jul; 65(1):145-8. PubMed ID: 6930511
[TBL] [Abstract][Full Text] [Related]
38. Dose response relationship of methotrexate in combination with cisplatin in murine bladder cancer.
Brausi M; Blatnik A; Soloway MS
Urology; 1990 Mar; 35(3):253-6. PubMed ID: 2316090
[TBL] [Abstract][Full Text] [Related]
39. Orthotopic implantation of primary N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide-induced bladder cancer in bladder submucosa: an animal model for bladder cancer study.
Ibrahiem EH; Nigam VN; Brailovsky CA; Madarnas P; Elhilali M
Cancer Res; 1983 Feb; 43(2):617-22. PubMed ID: 6848183
[TBL] [Abstract][Full Text] [Related]
40. Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II).
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):561-70. PubMed ID: 9679929
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
